There are concerns the protests we are seeing across the nation and around the globe following the death of George Floyd at the hands of Minneapolis police will set off another COVID-19 wave. The mayor of Los Angeles is concerned the gatherings will become “super spreader” events.
Of course, one of the major challenges of the novel coronavirus is the fact that some people can unknowingly be carriers. The BBC recently published a story about this unique and troubling aspect of the disease.
Eli Lilly says it has started human trials of an antibody therapy designed to treat COVID-19. Results are expected in late June.
There’s new information today about remdesivir, the drug developed by Gilead Sciences to treat COVID-19. According to new research results, the drug has helped patients with moderate disease recover more quickly when they received it for five days. However, the benefit was not statistically significant when given for 10 days. An earlier study showed that patients with severe disease who received remdesivir recovered four days faster than similar patients who received placebo.
There are also a couple of noteworthy research stories from overseas. Russia says it will start giving its first approved coronavirus drug to patients next week. They say tests of the drug favipiravir show it can successfully treat the virus. Meanwhile in South Korea, the drug company Celltrion says it has developed a medication that can lead to a 100-fold reduction in the viral load of COVID-19 in animal tests.
‹ More News